miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations

https://doi.org/10.1016/j.mcp.2019.101436Get rights and content

Highlights

  • 68 miRNAs were differentially expressed in CLL B lymphocytes.

  • miR-15a/miR-16-1 exhibited no deregulation in Uygur CLL patients.

  • miR-29b, miR-181a and miR-181b correlated with IGVH mutations.

  • miR-34a, miR-29b and miR-181b correlated with p53 mutations.

  • low miR-34a and miR-29b expression correlated with poor TFS.

Abstract

The abnormal expression of miRNAs may play critical roles in the occurrence, development and prognosis of chronic lymphocytic leukemia (CLL), with potential ethnic differences being involved. p53 and immunoglobulin heavy chain variable region gene (IGVH) mutations were monitored and miRNA profile screening of CD19 + cells from Uygur CLL patients was performed, analyzed by miRNA arrays and verified using real-time PCR. There were 68 differentially expressed miRNAs in CD19 + B lymphocytes obtained from 6 Uygur CLL patients, of which miR-1295, miR-29b, miR-34a, miR-21 and miR-29c were the 5 most upregulated, and miR-181a, miR-126, miR-181b, miR-125a-5p and miR199b the 5 most downregulated miRNAs. miR-15a/miR-16-1 which might be important drivers of the disease, were not eliminated by profile screening. From the 68 differentially expressed miRNAs, 5 previously-reported CLL-related miRNAs were selected for further confirmation analyses, from which expression levels of miR-29b, miR-34a and miR-155 were found to be increased while miR-181a and miR-181b decreased. However, there were no differences in the expression levels of miR-15a/miR-16-1 between CLL patients and healthy donors, but the expression levels of miR-15a/miR-16-1 in CLL patients with a 13q deletion was depressed. In addition, there was no difference in the expression level of the above 7 miRNAs between 44 Han and 40 Uygur CLL patients. The expression levels of miR-29b, miR-181a and miR-181b correlated with IGVH mutations, while the expression levels of miR-34a, miR-29b and miR-181b correlated with a p53 abnormality in 84 Uygur and Han CLL patients. Taking p53 abnormality as the cut-off value criteria, low expression levels of miR-34a (cut-off value 4.65, P = 0.02) and miR-29b (cut-off value 4.71, P = 0.009) hinted at a poor treatment-free survival (TFS) prognosis for all CLL patients. Thus miR-34a and miR-29b may represent useful indicators for the prognosis of both Uygur and Han CLL patients.

Introduction

Chronic lymphocytic leukemia (CLL) is a disease of mature B lymphocytes with cloning and proliferative tumor features that lead to lymphocytes aggregating in peripheral blood, bone marrow, lymph glands and the spleen. The incidence rate of CLL in the Occident (i.e. the western world, especially the countries of Europe and America) is significantly higher than in Asian regions [1]. These differences may be related to ethnicity, the geographical environment, living habits or genetic predisposition [[2], [3], [4], [5], [6], [7], [8]]. Uygur is a major group of people living in Xinjiang, China. Research by anthropologists found that the genomic composition of Uygur people has a closer relationship with Caucasians [9]. In recent years, the effects of abnormal expression of various miRNAs have received much attention, particularly with regard to the pathogenesis of CLL and its prognosis. Research has shown that there is a specific abnormity of expression of miRNAs in CLL patients, which can be an indicator for both disease diagnosis and prognosis [[10], [11], [12]].

In addition, CLL miRNAs expression profiles might have an ethnic component according to several previous studies [[13], [14], [15]]. The incidence of CLL in Asian countries is significantly lower than in Europe and the US. In China, the incidence of CLL only accounts for 1.26–3.5% of leukemias [16], leading to few related reports. Li et al. (2011) first applied gene chip technology containing 866 human miRNAs to screen the miRNA expression profile in a Han population and found that 31 miRNAs were differentially expressed. Five miRNAs (miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b) were selected for expression verification and related studies [17].

Therefore, in the present study, gene chip techniques were employed to measure miRNA expression in Uygur CLL patients and to compare the results with Han CLL patients in order to establish whether there were any ethnic differences. In addition, prognosis values were analyzed combined with current known prognostic factors.

Section snippets

Characteristic information about CLL patients of Uygur and Han origin and their health control

This study was approved and monitored by the ethics committee of the People's Hospital of Xinjiang Uygur autonomous region. Each enrolled individual signed an informed consent notification. A total of 84 cases of CLL patients in the People's Hospital of Xinjiang Uygur Autonomous Region from June 2011 to December 2017 were analyzed (including 40 cases in the Uygur group and 44 cases in the Han group); 30 healthy Uygur and 10 healthy Han subjects served as the control (Fig. 1). Inclusion criteria

Differential analysis of miRNA expressing profile between Uygur CLL cancer cells and Uygur normal B lymphocytes

Six cases of Uygur CLL patients at initial diagnosis were selected for miRNA gene chip screening. The clinical and biological characteristics of cancer cells from these patients are summarized in Table 1. Five cases presented with IGVH mutations and no case was positive for a p53 mutation. All cases were negative for ZAP70 and 1 patient had trisomy 12 and del11q23 mutations. CD38 was expressed in Patient No. 3 and Del11q14 mutation in Patient No. 6, implying that both of them had a poorer

Discussion

Currently, much research has been undertaken into differential expression of miRNAs in CLL patients [12,17,29]. Unfortunately, there is a great deal of inconsistency in the research results published in various countries, due to differences in the technical methods used, specimen sources and also the complexity of the mechanisms underlying CLL.

In the present study, for the first time we collected Uygur CLL cancer cells and normal CD19 positive cells and employed gene chips containing 1733 human

Conclusions

Our study revealed that there was no significant difference in miRNA expression levels between Uygur and Han CLL patients. The expression levels of miR-15a and miR-16-1 were not deregulated in Uygur and Han CLL, which is different from the most studies in the Occident and might due to the differentiation of the karyotyping distribution. In addition, the particularly low expression of miR-29b and miR-34a represent indicators for the prognosis of both Uygur and Han CLL patients.

Funding sources

This study was supported by the National Natural Science Foundation of China (Grant number: 81460033) and the Natural Science Foundation of Xinjiang Uygur Autonomous Region (Grant number 2017D01C116).

Author contribution

YL, XW and MM was responsible for the conception and design of the study. All authors were responsible for the acquisition and/or analysis of data; furthermore, YL, HL and ZK were in charge of statistical analysis. YL drafted the manuscript; YL and HL revised and commented on the draft, and all authors read and approved the final version of the submitted manuscript.

References (65)

  • K. Vargova et al.

    MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia

    Blood

    (2011)
  • R. Visone et al.

    miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia

    Blood

    (2011)
  • T. Zenz et al.

    miR-34a as part of the resistance network in chronic lymphocytic leukemia

    Blood

    (2009)
  • A. Fassina et al.

    The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies

    Lab. Investig.

    (2012)
  • B. Cui et al.

    MicroRNA-155 influences B- cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia

    Blood

    (2014)
  • R. Visone et al.

    Kary-otype-specific microRNA signaturein chronic lymphocytic leukemia

    Blood

    (2009)
  • S. Rossi et al.

    MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

    Blood

    (2010)
  • M. Hernández-Sánchez et al.

    MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion

    Leuk. Res.

    (2016)
  • F. Van Bockstaele et al.

    Prognostic markers in chronic lymphocytic leukemia: a comprehensive review

    Blood Rev.

    (2009)
  • B. Friedrichs et al.

    High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia

    Leuk. Res.

    (2011)
  • R. Ruchlemer et al.

    Geography, ethnicity and "roots" in chronic lymphocytic leukemia

    Leuk. Lymphoma

    (2013)
  • S.I. Berndt et al.

    Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia

    Nat. Commun.

    (2016)
  • S.I. Berndt et al.

    Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia

    Nat. Genet.

    (2013)
  • M.C. Di Bernardo et al.

    A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

    Nat. Genet.

    (2008)
  • P. Lichtenstein et al.

    Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland

    N. Engl. J. Med.

    (2000)
  • H.E. Speedy et al.

    A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia

    Nat. Genet.

    (2014)
  • G.A. Calin et al.

    A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia

    N. Engl. J. Med.

    (2005)
  • M. Mraz et al.

    MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia

    Leuk. Lymphoma

    (2013)
  • D.L. Zanette et al.

    miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

    (2007)
  • C. Nabhan et al.

    The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras

    Am. J. Hematol.

    (2014)
  • Y.P. Zhang et al.

    Immunoglobulin variable heavy chain region genetic constitution and mutation status in Chinese patients with chronic lymphocytic leukemia

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

    (2009)
  • H.J. Dong et al.

    The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)

    Ann. Hematol.

    (2011)
  • Cited by (7)

    View all citing articles on Scopus
    1

    Yan Li and Min Mao contributed equally to this article.

    View full text